BioLife Solutions Shares Edge Lower On Latest SEC Disclosures
ACADIA Pharmaceuticals closed at $21.72, up 1.3% with 1.12 million shares traded, trailing broader biotech gains. Investors are focused on Phase 2 trial data for remlifanserin in Alzheimer’s disease psychosis, expected between August and October. Quarterly revenue rose to $268.1 million, but net income dropped to $3.6 million as costs increased.